Crosslink Capital Lowered Lam Research (LRCX) Stake; Intra-cellular Therapies Has 2.77 Sentiment

January 14, 2018 - By Michael Collier

Crosslink Capital Inc decreased Lam Research (LRCX) stake by 36.32% reported in 2017Q3 SEC filing. Crosslink Capital Inc sold 49,670 shares as Lam Research (LRCX)’s stock rose 32.64%. The Crosslink Capital Inc holds 87,093 shares with $16.12 million value, down from 136,763 last quarter. Lam Research now has $30.53B valuation. The stock decreased 0.32% or $0.61 during the last trading session, reaching $188.51. About 2.79 million shares traded or 3.24% up from the average. Lam Research Corporation (NASDAQ:LRCX) has risen 107.86% since January 14, 2017 and is uptrending. It has outperformed by 91.16% the S&P500.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including ParkinsonÂ’s and AlzheimerÂ’s disease. The company has market cap of $1.03 billion. The firm is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders. It currently has negative earnings. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease.

Since September 11, 2017, it had 0 insider buys, and 10 insider sales for $7.30 million activity. $138,750 worth of Lam Research Corporation (NASDAQ:LRCX) was sold by NEWBERRY STEPHEN G. 15,638 shares valued at $2.75M were sold by ARCHER TIMOTHY on Monday, September 18.

Analysts await Lam Research Corporation (NASDAQ:LRCX) to report earnings on January, 24. They expect $3.67 earnings per share, up 63.84% or $1.43 from last year’s $2.24 per share. LRCX’s profit will be $594.33M for 12.84 P/E if the $3.67 EPS becomes a reality. After $3.46 actual earnings per share reported by Lam Research Corporation for the previous quarter, Wall Street now forecasts 6.07% EPS growth.

Among 23 analysts covering Lam Research Corporation (NASDAQ:LRCX), 21 have Buy rating, 0 Sell and 2 Hold. Therefore 91% are positive. Lam Research Corporation had 69 analyst reports since September 17, 2015 according to SRatingsIntel. On Thursday, January 26 the stock rating was maintained by Cowen & Co with “Outperform”. The firm has “Outperform” rating given on Wednesday, October 21 by Cowen & Co. The rating was maintained by B. Riley & Co with “Buy” on Thursday, October 20. Needham maintained Lam Research Corporation (NASDAQ:LRCX) rating on Friday, September 1. Needham has “Buy” rating and $200.0 target. B. Riley & Co maintained the stock with “Buy” rating in Wednesday, October 18 report. Morgan Stanley maintained the shares of LRCX in report on Wednesday, October 18 with “Overweight” rating. As per Thursday, December 7, the company rating was upgraded by Nomura. The stock has “Buy” rating by Instinet on Thursday, December 7. The rating was maintained by Needham with “Buy” on Thursday, July 27. The firm earned “Buy” rating on Tuesday, June 13 by UBS.

Investors sentiment increased to 1.02 in 2017 Q3. Its up 0.04, from 0.98 in 2017Q2. It is positive, as 51 investors sold LRCX shares while 238 reduced holdings. 87 funds opened positions while 207 raised stakes. 146.35 million shares or 1.92% less from 149.22 million shares in 2017Q2 were reported. Putnam Invests Ltd Liability has 0.08% invested in Lam Research Corporation (NASDAQ:LRCX). Victory Cap holds 0.13% of its portfolio in Lam Research Corporation (NASDAQ:LRCX) for 318,462 shares. Martingale Asset Mgmt Lp invested 0.07% in Lam Research Corporation (NASDAQ:LRCX). Bb&T Secs Lc holds 3,688 shares. Tnb Financial invested in 1,229 shares or 0.04% of the stock. Bridgeway Cap stated it has 485,906 shares or 1.03% of all its holdings. Renaissance Technology Lc holds 0.15% of its portfolio in Lam Research Corporation (NASDAQ:LRCX) for 680,456 shares. Strategy Asset Managers Lc owns 23,550 shares or 0.89% of their US portfolio. Voloridge Invest Mgmt Ltd Com owns 135,697 shares. Miracle Mile Advsrs Lc reported 0.04% in Lam Research Corporation (NASDAQ:LRCX). Comml Bank Of Montreal Can, a Ontario – Canada-based fund reported 1.55 million shares. Franklin Resources stated it has 1.22 million shares. Lockheed Martin Inv Company owns 10,000 shares. Products Prtn Ltd Limited Liability Company accumulated 0.85% or 138,690 shares. Balyasny Asset Management Ltd Llc owns 81,540 shares for 0.06% of their portfolio.

Since January 1, 0001, it had 3 insider buys, and 8 insider sales for $11.38 million activity.

Analysts await Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) to report earnings on March, 7. They expect $-0.51 EPS, up 20.31% or $0.13 from last year’s $-0.64 per share. After $-0.53 actual EPS reported by Intra-Cellular Therapies, Inc. for the previous quarter, Wall Street now forecasts -3.77% EPS growth.

The stock increased 2.55% or $0.47 during the last trading session, reaching $18.87. About 435,257 shares traded. Intra-Cellular Therapies, Inc. (ITCI) has declined 68.76% since January 14, 2017 and is downtrending. It has underperformed by 85.46% the S&P500.

Rhenman & Partners Asset Management Ab holds 2.38% of its portfolio in Intra-Cellular Therapies, Inc. for 1.18 million shares. Bvf Inc Il owns 950,000 shares or 1.91% of their US portfolio. Moreover, Bb Biotech Ag has 0.96% invested in the company for 2.20 million shares. The Massachusetts-based Clough Capital Partners L P has invested 0.7% in the stock. Perceptive Advisors Llc, a New York-based fund reported 929,460 shares.

Ratings analysis reveals 50% of Intra-Cellular Therapies’s analysts are positive. Out of 4 Wall Street analysts rating Intra-Cellular Therapies, 2 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. ITCI was included in 4 notes of analysts from September 29, 2016. The firm has “Overweight” rating given on Friday, December 16 by Cantor Fitzgerald. The stock has “Neutral” rating by SunTrust on Thursday, September 29. JMP Securities downgraded Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) on Thursday, September 29 to “Mkt Perform” rating. The stock of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) earned “Outperform” rating by RBC Capital Markets on Thursday, September 29.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts